The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
The transaction will take place in two tranches, with IMCD now acquiring 80% of Siliconas y Químicos’ share capital and the remaining 20% in 2022
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The company reported total income of Rs.38952 crores during the 12 months period ended March 31, 2021
The company's focus is on development of molecules in which it has core competencies, rather than on import substituting products.
Yasho Industries Ltd has reported total income of Rs.369.52 crores during the 12 months period ended March 31, 2021
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Many leading Indian chemical companies tapped the IPO route to raise funds worth approximately Rs. 4,000 crores during FY 2020-21
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.269.32 crores for FY ended March 31, 2021
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
BASF’s simulation technology optimizes loading behavior and enables metal replacement
Its core operating income was ¥147.6 billion
Net sales from continuing operations of $753 million, an increase of 10% compared with $687 million in the prior year period
Provide innovative, eco-friendly solutions and service packages for dealers to meet volatile organic compounds targets
The High Court of Mumbai has ruled in favour of Sadhana Nitro Chem in the writ petition that it filed against Cibil Transunion
The agreement will help ensure wider reach and access to patients in India
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
Subscribe To Our Newsletter & Stay Updated
